Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Thrivent Financial for Lutherans Acquires 5,440 Shares of Jazz Pharmaceuticals PLC $JAZZ
05:08am, Wednesday, 24'th Dec 2025
Thrivent Financial for Lutherans raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 38.1% in the second quarter, according to its most recent 13F filing with the Securities an
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
04:15pm, Wednesday, 17'th Dec 2025
DUBLIN , Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 Investor W
Jazz Pharmaceuticals PLC $JAZZ Holdings Lowered by California Public Employees Retirement System
03:57am, Friday, 12'th Dec 2025
California Public Employees Retirement System cut its stake in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 15.7% in the undefined quarter, according to its most recent Form 13F filing with the Securiti
Contrasting Jazz Pharmaceuticals (NASDAQ:JAZZ) and Apogee Therapeutics (NASDAQ:APGE)
02:00am, Thursday, 11'th Dec 2025
Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and Apogee Therapeutics (NASDAQ: APGE - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 05'th Dec 2025
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, in
Trials, Sales Wins Sends Jazz Pharmaceuticals Higher
07:12am, Friday, 05'th Dec 2025
Jazz Pharmaceuticals PLC (JAZZ) shares up 352% since Big Money bought big in 2015.
Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, t
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
01:13pm, Tuesday, 02'nd Dec 2025
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
10:16am, Wednesday, 26'th Nov 2025
JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.
The shortened holiday week is here, and the futures are trading higher this morning.
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
04:15pm, Tuesday, 18'th Nov 2025
DUBLIN , Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will pa
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
01:21pm, Tuesday, 18'th Nov 2025
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence
04:53pm, Monday, 17'th Nov 2025
Jazz Pharmaceuticals plc surged over 20% after positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer. JAZZ's diversified portfolio, strong Q3 earnings, and upgraded 2025 revenue guidance
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
02:43pm, Monday, 17'th Nov 2025
Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in com
